Secondary endpoint results included the finding that nearly twice as many patients achieved clinical response with upadacitinib (61 percent, n=22/36 and 57 percent, n=21/37 in the 24 mg and 6 mg twice daily groups, respectively) compared with the placebo group (32 percent, n=12/37, P≤0.05 for both comparisons).Significantly more patients receiving upadacitinib doses greater than or equal to 6 mg twice daily achieved endoscopic response compared to placebo (P≤0.01 for all comparisons).- Phase 2 study showed positive results in a moderately to severely active Crohn's disease patient population, the majority of whom had previously failed two or more biologics- Promising Phase 2 dose-ranging study supports advancement to Phase 3- Safety profile of upadacitinib in this Crohn's disease study was consistent with that observed in the upadacitinib investigational rheumatoid arthritis clinical trials /PRNewswire/ -- Abb Vie (NYSE: ABBV), a global biopharmaceutical company, today announced promising results from CELEST, a Phase 2, randomized, double-blind, placebo-controlled study evaluating upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, in adult patients with moderately to severely active Crohn's disease.These data are being presented today during the Clinical Science: Late-Breaking Abstract Plenary Session (Presentation #874h) at Digestive Disease Week® 2017."Crohn's disease is a serious, chronic disease with symptoms and complications that can have a major impact on patients' daily lives, and additional treatments are needed to improve the prognosis for many living with the disease," said ."The CELEST study included patients with difficult-to-treat Crohn's disease who failed two or more biologics.I've called the organizers a few times before but they're unwilling to sell individual tickets as they'd rather sell by the table. SG conference are anything like this, the whole trip to Singapore would be worth it. Don't you think she bears an uncanny resemblance to Jessica Simpson? Miss Singapore was scheduled to do an Aikido martial arts demonstration. I spoke to Miss Singapore when I bumped into the contestants during lunch a few days ago. Its quite clear to me that she's not the most confident one of the group. " btw, that's Miss Tunisia standing on the far right. This wraps up my account of the Kuching preview show.
As you can imagine, we've had a lot going on, and this mama-to-be just needed a tiny break. Just got back from the Kuching preview show of the Miss Tourism Pageant 2005 last night. The minister's speech can be summed up as follows: 1. He did say something to that effect.) Anyone wanna bet his stupid speech is gonna make the headlines tomorrow? Letting someone like me sneak into the Miss Tourism Pageant was the last of the organizer's concerns. Miss Malaysia easily had the best performance of the night. Miss China is damn skinny, but she got a nice albeit flat face though.The tickets are expensive at RM300 per person and are difficult to get by. Miss USA looks like she has a dislocated her hip bones playing the hoola hoops. Miss Romania looks like a total doll without Miss Slovakia's plasticky feel. Miss Singapore Celest Foo definitely had the BEST evening wear of the night. Coincidentally I'm in Singapore right now, looking forward to attending the Blogger. Pop by DXO at the Esplanade if you're in town alright.These positive results support advancement into Phase 3 to further explore a potential new treatment option that may address the unmet needs of patients living with this challenging disease." The Phase 2 study evaluated the safety and efficacy of multiple dosing regimens of upadacitinib after 16 weeks of treatment.The positive results support advancement of the program into Phase 3.